Page last updated: 2024-10-18

dihydroxyphenylalanine and Neuroendocrine Tumors

dihydroxyphenylalanine has been researched along with Neuroendocrine Tumors in 55 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Neuroendocrine Tumors: Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.

Research Excerpts

ExcerptRelevanceReference
"(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies."8.9018F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014)
"In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors."8.846-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008)
"This work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation."7.8018F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. ( Bachellier, P; Detour, J; Duclos, B; Gabriel, S; Goichot, B; Imperiale, A; Kurtz, JE; Namer, IJ; Rust, E; Taïeb, D, 2014)
"(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies."4.9018F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014)
"In recent years, 6-l-18F-fluorodihydroxyphenylalanine (18F-DOPA) PET has emerged as a new diagnostic tool for the imaging of neuroendocrine tumors."4.846-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications. ( Brouwers, AH; Chirakal, R; Gulenchyn, KY; Jager, PL; Koopmans, KP; Marriott, CJ, 2008)
"This work was performed to evaluate the performance of (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) PET/CT in detecting primary neuroendocrine tumors (NETs) occult on morphologic and functional imaging, in relation to tumor origin and differentiation."3.8018F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. ( Bachellier, P; Detour, J; Duclos, B; Gabriel, S; Goichot, B; Imperiale, A; Kurtz, JE; Namer, IJ; Rust, E; Taïeb, D, 2014)
" 6-L-¹⁸F-fluorodihydroxyphenylalanine (¹⁸F-FDOPA) positron emission tomography (PET) is a relatively new metabolic imaging tracer proposed for the use of localizing sites of neuroendocrine tumors."3.78Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome. ( Gesuwan, K; Herscovitch, P; Kebebew, E; Kitano, M; Linehan, WM; Millo, C; Nilubol, N; Weisbrod, AB, 2012)
"(68)Ga-DOTA-Tyr3-octreotide positron emission tomography ((68)Ga-DOTA-TOC PET) and (18)F-fluoro-L-dihydroxyphenylalanine PET ((18)F-DOPA PET) are emerging modalities for imaging of neuroendocrine tumors."3.76Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. ( Gabriel, M; Henninger, B; Kendler, D; Knoflach, M; Kroiss, A; Putzer, D; Virgolini, IJ; Vonguggenberg, E; Warwitz, B, 2010)
"[(11)C]-5-Hydroxytryptophan ([(11)C]HTP) and 6-[(18)F]fluoro-3,4-dihydroxy-l-phenylalanine ([(18)F]FDOPA) are used to image neuroendocrine tumors with positron emission tomography."3.74Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. ( Brouwers, AH; de Vries, EG; Dierckx, RA; Doorduin, J; Elsinga, PH; Jager, PL; Kema, IP; Koopmans, KP; Neels, OC; Timmer-Bosscha, H; van Waarde, A; Vercauteren, L, 2008)
"(68)Ga-DOTA-TATE PET delineated metastases in 54 of 55 positive metastatic tumour regions in contrast to 29 of 55 delineated by (18)F-DOPA PET."1.35Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. ( Auernhammer, CJ; Bartenstein, P; Göke, B; Haug, A; Pöpperl, G; Schmidt, G; Tiling, R; Wängler, B, 2009)

Research

Studies (55)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (20.00)29.6817
2010's36 (65.45)24.3611
2020's8 (14.55)2.80

Authors

AuthorsStudies
Morland, D3
Jallerat, P1
Brixi, H2
Cadiot, G3
Papathanassiou, D2
Deguelte, S3
Jallet, L1
Lelièvre, M1
Triumbari, EKA1
Perrier, M1
Jullien, M1
Reichert, T1
D'Anella, P1
Castinetti, F1
Barlier, A1
Brue, T1
Taieb, D4
Cuny, T1
Barachini, O1
Bernt, R1
Mirzaei, S1
Pirich, C1
Hergan, K1
Zandieh, S1
Deleval, N1
Pesque, L1
Dieudonné, A1
Viry, F1
Hentic, O1
Lebtahi, R1
Ruszniewski, P1
de Mestier, L1
Ansquer, C2
Touchefeu, Y1
Faivre-Chauvet, A1
Leux, C1
Le Bras, M1
Régenet, N1
Fleury, V1
Maucherat, B1
Senellart, H1
Guyetant, S1
Carlier, T1
Scotet-Cérato, E1
Rauscher, A1
Frampas, E1
Kraeber-Bodéré, F1
Veenstra, EB1
de Groot, DJA1
Brouwers, AH6
Walenkamp, AME3
Noordzij, W3
Cuccurullo, V2
Prisco, MR1
Di Stasio, GD2
Mansi, L2
Bozkurt, MF1
Virgolini, I1
Balogova, S2
Beheshti, M1
Rubello, D7
Decristoforo, C1
Ambrosini, V5
Kjaer, A1
Delgado-Bolton, R1
Kunikowska, J1
Oyen, WJG1
Chiti, A2
Giammarile, F1
Sundin, A1
Fanti, S7
Berends, AMA1
Kerstens, MN1
Bolt, JW1
Links, TP1
Korpershoek, E1
de Krijger, RR1
van Etten, B1
Kats-Ugurlu, G1
van der Horst-Schrivers, ANA1
Gornes, H1
Vaysse, C1
Deslandres, M1
Perallon, R1
Chantalat, E1
Rimailho, J1
Bergeret, S1
Charbit, J1
Bera, G1
Chanson, P1
Lussey-Lepoutre, C1
de Hosson, LD1
van der Loo-van der Schaaf, AM1
Boellaard, R1
van Snick, JH1
de Vries, EGE1
Talbot, JN1
Nataf, V1
Michaud, L1
Huchet, V1
Kerrou, K1
Montravers, F1
Imperiale, A7
Addeo, P1
Averous, G1
Namer, IJ4
Bachellier, P4
Rust, E2
Gabriel, S1
Detour, J1
Goichot, B2
Duclos, B1
Kurtz, JE1
Schillaci, O1
Minn, H2
Kemppainen, J1
Kauhanen, S2
Forsback, S1
Seppänen, M2
Santhanam, P1
van Beek, AP1
Tio, RA1
van der Horst-Schrivers, AN1
de Vries, EG2
van Ginkel, B1
Walenkamp, AM1
Glaudemans, AW2
Slart, RH2
Dierckx, RA3
Kuik, WJ1
Kema, IP2
Zijlma, R1
Neumann, KD1
DiMagno, SG1
Elsinga, PH2
Morigi, JJ1
Nanni, C6
Castellucci, P3
Garnon, J2
Gangi, A2
Stormezand, GN1
Shamim, SA1
Kumar, A1
Kumar, R1
Gauthé, M1
Lièvre, A1
Alberini, JL1
Pacak, K1
Cazzato, RL1
Ramamurthy, N1
Tsoumakidou, G1
Caudrelier, J1
Rao, P1
Koch, G1
Helali, M1
Heimburger, C1
Rohr, S1
Ito, T1
Jensen, RT1
Trapani, A1
Tricarico, D1
Mele, A1
Maqoud, F1
Mandracchia, D1
Vitale, P1
Capriati, V1
Trapani, G1
Dimiccoli, V1
Tolomeo, A1
Scilimati, A1
Arbizu, J1
Rodriguez-Fraile, M1
Dominguez-Prado, I1
Garrastachu, P1
Rotellar, F1
Sangro, B1
Richter, JA1
Neels, OC1
Koopmans, KP2
Jager, PL2
Vercauteren, L1
van Waarde, A1
Doorduin, J1
Timmer-Bosscha, H1
Haug, A1
Auernhammer, CJ1
Wängler, B1
Tiling, R1
Schmidt, G1
Göke, B1
Bartenstein, P1
Pöpperl, G1
Nuutila, P1
Putzer, D1
Gabriel, M1
Kendler, D1
Henninger, B1
Knoflach, M1
Kroiss, A1
Vonguggenberg, E1
Warwitz, B1
Virgolini, IJ1
Schiesser, M2
Veit-Haibach, P2
Muller, MK1
Weber, M1
Bauerfeind, P1
Hany, T1
Clavien, PA2
Soyka, J1
Strobel, K1
Schaefer, NG1
Hesselmann, R1
Hany, TF1
Van Binnebeek, S1
Karges, W1
Mottaghy, FM1
Chondrogiannis, S1
Grassetto, G1
Marzola, MC2
Rampin, L1
Massaro, A1
Bellan, E1
Ferretti, A1
Mazza, A1
Al-Nahhas, A3
Weisbrod, AB1
Kitano, M1
Gesuwan, K1
Millo, C1
Herscovitch, P1
Nilubol, N1
Linehan, WM1
Kebebew, E1
Lopci, E1
Piccardo, A1
Altrinetti, V1
Garaventa, A1
Pession, A1
Cistaro, A1
Villavecchia, G1
Wong, KK1
Waterfield, RT1
Scarsbrook, AF1
Chowdhury, FU1
Gross, MD1
Boulanger, C1
Roedlich, MN1
Ollier, JC1
Schneegans, O1
Sorschag, M1
Malle, P1
Gallowitsch, HJ1
Treglia, G1
Castaldi, P1
Rufini, V1
Becherer, A1
Szabó, M1
Karanikas, G1
Wunderbaldinger, P1
Angelberger, P1
Raderer, M1
Kurtaran, A1
Dudczak, R1
Kletter, K1
Tomassetti, P2
Campana, D2
Farsad, M1
Montini, G2
Franchi, R2
Seibyl, JP1
Chen, W1
Silverman, DH1
Chirakal, R1
Marriott, CJ1
Gulenchyn, KY1
Rizzello, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma[NCT02021604]Phase 1250 participants (Anticipated)Interventional2013-10-09Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

13 reviews available for dihydroxyphenylalanine and Neuroendocrine Tumors

ArticleYear
Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
    Current radiopharmaceuticals, 2017, Volume: 10, Issue:2

    Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Nuclear Medicine; Oct

2017
Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
    Current radiopharmaceuticals, 2019, Volume: 12, Issue:2

    Topics: Animals; Dihydroxyphenylalanine; Dimerization; Edetic Acid; Fluorodeoxyglucose F18; Glucagon-Like Pe

2019
Novel PET tracers: added value for endocrine disorders.
    Endocrine, 2019, Volume: 64, Issue:1

    Topics: Dihydroxyphenylalanine; Endocrine System Diseases; Fluorodeoxyglucose F18; Gallium Radioisotopes; Hu

2019
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:6

    Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorode

2013
18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
    PET clinics, 2014, Volume: 9, Issue:1

    Topics: Adrenal Gland Neoplasms; Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Humans; Intestinal Neopl

2014
Role of (18) F-FDOPA PET/CT imaging in endocrinology.
    Clinical endocrinology, 2014, Volume: 81, Issue:6

    Topics: Adrenal Gland Neoplasms; Carbidopa; Carcinoid Tumor; Carcinoma, Neuroendocrine; Dihydroxyphenylalani

2014
Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP).
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2015, Volume: 59, Issue:1

    Topics: 5-Hydroxytryptophan; Carbon Radioisotopes; Dihydroxyphenylalanine; Gallium Radioisotopes; Humans; Im

2015
PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
    PET clinics, 2015, Volume: 10, Issue:3

    Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gast

2015
Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
    Current opinion in endocrinology, diabetes, and obesity, 2017, Volume: 24, Issue:1

    Topics: Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Glucagon-Like Peptide 1; Humans; Molecular Im

2017
Contemporary nuclear medicine imaging of neuroendocrine tumours.
    Clinical radiology, 2012, Volume: 67, Issue:11

    Topics: Chromaffin System; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Ne

2012
Nuclear medicine in NET.
    Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:19-20

    Topics: Biomarkers, Tumor; Cell Proliferation; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radio

2012
3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
    Seminars in nuclear medicine, 2007, Volume: 37, Issue:6

    Topics: Adrenal Gland Neoplasms; Amino Acids; Brain Neoplasms; Caudate Nucleus; Dihydroxyphenylalanine; Fluo

2007
6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, Volume: 49, Issue:4

    Topics: Adenoma, Islet Cell; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Neuroendocrine Tumors; Pancrea

2008

Trials

3 trials available for dihydroxyphenylalanine and Neuroendocrine Tumors

ArticleYear
18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR.
    Clinical nuclear medicine, 2012, Volume: 37, Issue:4

    Topics: Child; Dihydroxyphenylalanine; Female; Humans; Magnetic Resonance Imaging; Male; Multimodal Imaging;

2012
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Indium Radioisotopes; Male;

2004
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
    Nuclear medicine communications, 2007, Volume: 28, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Digestive System Neoplasms; Dihydroxyphenylalanine;

2007

Other Studies

39 other studies available for dihydroxyphenylalanine and Neuroendocrine Tumors

ArticleYear
Performances of 18F-FDOPA PET/CT in the Preoperative Evaluation of the Peritoneal Cancer Index in Small Intestine Neuroendocrine Tumors.
    Clinical nuclear medicine, 2022, Apr-01, Volume: 47, Issue:4

    Topics: Dihydroxyphenylalanine; Humans; Intestine, Small; Neuroendocrine Tumors; Positron Emission Tomograph

2022
Orbital Metastasis: A Rare but Typical Location of Small Intestine Neuroendocrine Tumor on 18F-FDOPA PET/CT.
    Clinical nuclear medicine, 2022, Aug-01, Volume: 47, Issue:8

    Topics: Dihydroxyphenylalanine; Humans; Intestinal Neoplasms; Intestine, Small; Neuroendocrine Tumors; Posit

2022
Bone metastases in midgut neuroendocrine tumors: imaging characteristics, distribution, and risk factors.
    Endocrine, 2022, Volume: 78, Issue:2

    Topics: Bone Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Posit

2022
Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient.
    Annales d'endocrinologie, 2020, Volume: 81, Issue:1

    Topics: Dihydroxyphenylalanine; Female; Humans; Middle Aged; Multiple Endocrine Neoplasia Type 1; Neuroendoc

2020
The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract.
    BMC medical imaging, 2020, 02-24, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Diffusion Tensor Imaging; Dihydroxyphenylalanine; Female; Gastrointe

2020
Prognostic impact of bone metastases detected by
    European radiology, 2021, Volume: 31, Issue:6

    Topics: Aged; Dihydroxyphenylalanine; Humans; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis

2021
Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
    Clinical nuclear medicine, 2021, Mar-01, Volume: 46, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Intestinal Neoplasms; Male;

2021
Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
    Clinical nuclear medicine, 2021, Mar-01, Volume: 46, Issue:3

    Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide;

2021
Guideline for PET/CT imaging of neuroendocrine neoplasms with
    European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:9

    Topics: Dihydroxyphenylalanine; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Image Interpr

2017
False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
    European journal of endocrinology, 2018, Volume: 179, Issue:2

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; False Positive Reactions; Female; Huma

2018
Discovery of a neuroendocrine tumor of the caecum by mammary metastasis using 18F-DOPA-PET.
    The journal of obstetrics and gynaecology research, 2018, Volume: 44, Issue:12

    Topics: Adult; Breast Neoplasms; Cecal Neoplasms; Dihydroxyphenylalanine; Female; Humans; Neoplasm Metastasi

2018
Interlesional Heterogeneity of Metastatic Neuroendocrine Tumors Based on 18F-DOPA PET/CT.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:8

    Topics: Aged; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Neoplasm Me

2019
Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on ¹⁸F-FDOPA PET/CT.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:7

    Topics: Adult; Carbidopa; Diagnosis, Differential; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radiois

2013
18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:3

    Topics: Adult; Aged; Cohort Studies; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Multimodal I

2014
18F-DOPA and other radiopharmaceuticals for imaging unknown primary neuroendocrine tumors.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:3

    Topics: Dihydroxyphenylalanine; Female; Humans; Male; Multimodal Imaging; Neuroendocrine Tumors; Positron-Em

2014
Myocardial metastases on 6-[18F] fluoro-L-DOPA PET/CT: a retrospective analysis of 116 serotonin producing neuroendocrine tumour patients.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Carcinoid Heart Disease; Dihydroxyphenylalanine; Female; Heart Neoplasms; Humans; Male; Middle Aged;

2014
In vivo biodistribution of no-carrier-added 6-18F-fluoro-3,4-dihydroxy-L-phenylalanine (18F-DOPA), produced by a new nucleophilic substitution approach, compared with carrier-added 18F-DOPA, prepared by conventional electrophilic substitution.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:1

    Topics: Animals; Cell Line, Tumor; Dihydroxyphenylalanine; Drug Stability; Humans; Male; Mice; Neuroendocrin

2015
Simultaneous (18)F-FDOPA PET/CT-guided biopsy and radiofrequency ablation of recurrent neuroendocrine hepatic metastasis: further step toward a theranostic approach.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:6

    Topics: Ablation Techniques; Dihydroxyphenylalanine; Humans; Ileal Neoplasms; Image-Guided Biopsy; Liver; Li

2015
(18)F-FDOPA accumulation in traumatic rib fractures: a potential pitfall.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:6

    Topics: Diagnostic Errors; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Multimodal Imaging; Ne

2015
Primary Neuroendocrine Tumor in a Horseshoe Kidney With Positive 111In-Pentetreotide Somatostatin Receptor Scintigraphy and Negative 18F-DOPA PET/CT.
    Clinical nuclear medicine, 2015, Volume: 40, Issue:11

    Topics: Dihydroxyphenylalanine; Female; Fused Kidney; Humans; Middle Aged; Multimodal Imaging; Neuroendocrin

2015
(18)F-DOPA: the versatile radiopharmaceutical.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:6

    Topics: Biological Transport; Dihydroxyphenylalanine; Humans; Neuroendocrine Tumors; Nuclear Medicine; Radio

2016
18F-FDOPA PET/CT-Guided Radiofrequency Ablation of Liver Metastases from Neuroendocrine Tumours: Technical Note on a Preliminary Experience.
    Cardiovascular and interventional radiology, 2016, Volume: 39, Issue:9

    Topics: Adult; Catheter Ablation; Dihydroxyphenylalanine; Female; Humans; Liver; Liver Neoplasms; Male; Midd

2016
Small Bowel Carcinoid: The "Dancing Bowel Sign" on 18F-FDOPA PET/CT.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:12

    Topics: Adult; Carcinoid Tumor; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; Intestinal N

2016
A novel injectable formulation of 6-fluoro-l-DOPA imaging agent for diagnosis of neuroendocrine tumors and Parkinson's disease.
    International journal of pharmaceutics, 2017, Mar-15, Volume: 519, Issue:1-2

    Topics: Animals; beta-Cyclodextrins; Cell Line, Tumor; Chemistry, Pharmaceutical; Cysteine; Dihydroxyphenyla

2017
Whole body 18fluoro-L-dopa PET-CT: a useful tool for location and surgical guidance in primary carcinoid tumours.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:8

    Topics: Adolescent; Dihydroxyphenylalanine; Female; Humans; Neuroendocrine Tumors; Positron-Emission Tomogra

2008
Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.
    Cancer research, 2008, Sep-01, Volume: 68, Issue:17

    Topics: 5-Hydroxytryptophan; Animals; Cell Line, Tumor; Dihydroxyphenylalanine; Humans; Male; Mice; Mice, In

2008
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:5

    Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neopl

2009
18F-FDOPA: a multiple-target molecule.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2009, Volume: 50, Issue:12

    Topics: Adult; Biological Transport; Dihydroxyphenylalanine; Humans; Hyperinsulinism; Infant, Newborn; Neuro

2009
Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2010, Volume: 54, Issue:1

    Topics: Adolescent; Adult; Aged; Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Humans; Male; Middle

2010
Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
    The British journal of surgery, 2010, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neuroendo

2010
Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.
    European radiology, 2011, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Contrast Media; Dihydroxyphenylalanine; Female; Humans;

2011
Functional imaging of neuroendocrine tumors.
    Methods in molecular biology (Clifton, N.J.), 2011, Volume: 727

    Topics: 5-Hydroxytryptophan; Animals; Contrast Media; Dihydroxyphenylalanine; Dopamine; Ephedrine; Etomidate

2011
18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours.
    Nuclear medicine communications, 2012, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Dihydroxyphenylalanine; Female; Humans; Image Enh

2012
Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4

    Topics: Adult; Central Nervous System Neoplasms; Cohort Studies; Contrast Media; Dihydroxyphenylalanine; Fem

2012
Terminal ileum neuroendocrine incidentaloma in a patient with sporadic medullary thyroid carcinoma: findings from 18F-FDOPA PET/CT investigation.
    Clinical nuclear medicine, 2012, Volume: 37, Issue:8

    Topics: Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Female; Humans; Ileal Neoplasms; Incidental Findi

2012
(18)F-DOPA PET/CT revealed synchronous neuroendocrine tumors in two sisters with MEN2A syndrome.
    Endocrine, 2013, Volume: 43, Issue:2

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Carcinoma, Medullary; Dihydroxyphenylalanine; Female;

2013
18F-DOPA PET/CT and neuroendocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2006, Volume: 33, Issue:5

    Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron-Emission Tom

2006
68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.
    Nuclear medicine communications, 2008, Volume: 29, Issue:5

    Topics: Dihydroxyphenylalanine; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission T

2008
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
    European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:8

    Topics: Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Gastrointestinal Neoplasms; Humans; Lung Ne

2008